论文部分内容阅读
血栓治疗药——抗血小板药、纤维蛋白溶解系亢进药紧追世界第二位“巨型炸弹”盐酸氯吡格雷之后的竞争激化。开发的焦点从腺苷二磷酸(ADP)受体拮抗药转移到可逆性拮抗药。蛋白酶激活受体拮抗药等具有新作用机理药物的开发也在进行。抗血栓药不仅用于脑血管疾病的预防和治疗,同时也广泛应用在药物溶解支架安装和人工关节置换等外科手术后的血栓预防上,市场还在进一步扩大。负责止血的血小板,为了维
Thrombolytic drugs - antiplatelet drugs, hypertonic fibrinolytic drugs follow the world’s second “giant bomb” clopidogrel hydrochloride after the intensification of competition. The focus of development has shifted from adenosine diphosphate (ADP) receptor antagonists to reversible antagonists. Protease-activated receptor antagonists and other drugs with a new mechanism of action is also under development. Antithrombotic drugs are not only used in the prevention and treatment of cerebrovascular diseases, but also widely used in thromboprophylaxis after surgical operations such as drug-dissolving stent installation and artificial joint replacement, and the market is still being further expanded. Hemostatic platelets, in order to Victoria